NTRA · Natera Inc.
AI read · Neutral
The AI's read
Natera beat Q2 estimates with $752.8M revenue, raised FY26 guide to $2.85–2.91B, and reported 1.04M tests, led by oncology. Gross margin expanded to 64.5%, so the business shows clear operational leverage. The stock already rallied ~20% on the print, so a lot of the upside moved into the price today. That move reduces near-term asymmetry despite the strong quarter. We lean neutral here. The catalyst is real, but the market has largely front-run it, leaving limited immediate upside for fresh buyers.